Table 2

Novel selective lymphocyte trafficking inhibitors

Selective lymphocyte trafficking inhibitors
NameStudyUC/CrohnsMechanism of
Action		AuthorsResultsAdverse events
Vedolizumab subcutaneousVISIBLE 1 and 2Phase III/Phase IIIA4b7 inhibitorSandborn et al, 202020 UC→ 46.2% of moderate UC patients who responded to IV VDZ sustained remission.Reaction at injection site
Vermeire et al, 202218 CD→48% of moderate Crohn’s patients who responded to 2 infusions of VDZ have sustained remission at
week 52.
EtrolizumabHICKORY
LAUREL
GARDENIA		Phase III/IIIAnti- β7 subunit mAbPeyrin-Biroulet L et al, 2022.22
Vermeire S et al,
2022.23
Danese et al,
202224 		UC→Clinical remission (UC patients previously treated with anti-TNF) 18.5% vs 6.3% of placebo at week
14		UC flare,
Appendicitis,
Anaemia
Carotegrast
Methyl (AJM300)		Phase III/-Anti-a4 mAb
(a4b7 and a4b1)		Matsuoka et al,
2022.24 		UC→Clinical response in 46% of moderately active UC patients and endoscopic remission in 14% at week 8Nasopharyngitis

  • IV, intravenous; UC, ulcerative colitis; VDZ, vedolizumab.